{
    "clinical_study": {
        "@rank": "23325", 
        "arm_group": [
            {
                "arm_group_label": "Misoprostol", 
                "arm_group_type": "Active Comparator", 
                "description": "4 misoprostol tablets (Misotac\u00ae 200 micrograms tablet) dissolved in 20 ml of normal saline injected to umbilical vein"
            }, 
            {
                "arm_group_label": "Normal saline", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Normal saline 0.9%, 20 ml was injected in the umbilical vein in cases of retained placenta"
            }
        ], 
        "brief_summary": {
            "textblock": "Administration of intraumbilical misoprostol to women with retained placenta despite active\n      management of  third stage of labour reduces the need for manual removal of placenta and the\n       amount of blood loss vaginally."
        }, 
        "brief_title": "Intraumbilical Misoprostol in Retained Placenta", 
        "completion_date": {
            "#text": "March 2012", 
            "@type": "Actual"
        }, 
        "condition": "Retained Placenta", 
        "condition_browse": {
            "mesh_term": "Placenta, Retained"
        }, 
        "detailed_description": {
            "textblock": "Retained placenta (RP)is one of the complications of third stage of labour; it should be\n      managed promptly as it may cause severe bleeding, infection, maternal morbidity and\n      mortality .The current standard management of RP word wide, by manual removal  aims to\n      prevent these problems, but it is unsatisfactory method because it requires general\n      anaesthesia in hospital, It is an invasive procedure with its own serious complications of\n      bleeding, infection and genital tract injury. Umbilical vein injection of misoprostol is a\n      simple, safe method and  could  be performed at the place of delivery ."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  women having singleton pregnancy\n\n          -  28 weeks of gestation or more delivered vaginally\n\n          -  prolongation of the third stage of labour (more than 30 min) following     active\n             management of third stage of labour\n\n        Exclusion Criteria:\n\n          -  Who refused to participate in the trial\n\n          -  Multiple pregnancies\n\n          -  Previous Caesarean Section\n\n          -  Haemodynamically unstable\n\n          -  Severe anaemia (haemoglobin less than 8gm/dl)\n\n          -  Chorioamnionitis"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "45 Years", 
            "minimum_age": "15 Years"
        }, 
        "enrollment": {
            "#text": "46", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01840813", 
            "org_study_id": "HMU911"
        }, 
        "intervention": [
            {
                "arm_group_label": "Misoprostol", 
                "description": "It is a synthetic prostaglandin (PgE1 analogue)used as a uterotonic substance.", 
                "intervention_name": "Misoprostol", 
                "intervention_type": "Drug", 
                "other_name": "(Misotac)\u00ae tablet"
            }, 
            {
                "arm_group_label": "Normal saline", 
                "description": "It is a placebo group", 
                "intervention_name": "Normal saline", 
                "intervention_type": "Drug", 
                "other_name": "Normal saline 0.9%"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Misoprostol"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Intraumbilical misoprostol", 
            "Retained placenta", 
            "Active management of third stage of labour"
        ], 
        "lastchanged_date": "November 1, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Erbil city", 
                    "country": "Iraq", 
                    "state": "Kurdistan region", 
                    "zip": "383-65"
                }, 
                "name": "Maternity Teaching Hospital"
            }
        }, 
        "location_countries": {
            "country": "Iraq"
        }, 
        "number_of_arms": "2", 
        "official_title": "Intra-umbilical Injection of Misoprostol Versus Normal Saline in the Management of Retained Placenta: Intrapartum Placebo-controlled Trial", 
        "other_outcome": {
            "description": "Local applications of misoprostol through umbilical vein is associated with less side effects like shivering, fever, dizziness vomiting, flushes, nausea, abdominal pain and headache", 
            "measure": "Number of Participants with Adverse Events as a Measure of Safety and Tolabrity", 
            "safety_issue": "Yes", 
            "time_frame": "2  hours after umbilical vein injection of misoprostol"
        }, 
        "overall_official": [
            {
                "affiliation": "Hawler Medical University", 
                "last_name": "Shahla K. Alalaf, Clinical M.D", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": ", Shaheed Dr.Khalid General Hospital, Directorate of Health", 
                "last_name": "Sheelan S Rajab, High Diploma", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Iraq: Ethics Committee"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The administration of intraumbilical misoprostol to women with retained placenta despite active management of third stage of labour reduces the need for manual removal of placenta under general anaesthesia.", 
            "measure": "delivery of placenta by medical intervention", 
            "safety_issue": "Yes", 
            "time_frame": "30 minutes after the injection of misoprostol or normal saline in the umbilical vein"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01840813"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Hawler Medical University", 
            "investigator_full_name": "Assistant Prof. Shahla Alalaf", 
            "investigator_title": "Assistant Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "using intraumbilical misoprostol in women with retained placenta reduces the amount of blood loss vaginally.", 
            "measure": "vaginal bleeding after misoprostol use", 
            "safety_issue": "Yes", 
            "time_frame": "30 minutes after umbilical vein injection of misoprostol"
        }, 
        "source": "Hawler Medical University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hawler Medical University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2011", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}